$10.55
14.55% today
Nasdaq, Apr 04, 07:43 pm CET
ISIN
US8162121045
Symbol
RNAC
Sector
Industry

Cartesian Therapeutics Target price 2025 - Analyst rating & recommendation

Cartesian Therapeutics Classifications & Recommendation:

Buy
75%
Hold
25%

Cartesian Therapeutics Price Target

Target Price $37.33
Price $12.34
Potential
Number of Estimates 6
6 Analysts have issued a price target Cartesian Therapeutics 2026 . The average Cartesian Therapeutics target price is $37.33. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 8 analysts: 6 Analysts recommend Cartesian Therapeutics to buy, 2 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Cartesian Therapeutics stock has an average upside potential 2026 of . Most analysts recommend the Cartesian Therapeutics stock at Purchase.

Sales and Margin forecast 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Revenue Million $ 38.91 3.14
49.65% 91.92%
Net Margin -275.18% -2,403.04%
93.98% 773.27%

7 Analysts have issued a sales forecast Cartesian Therapeutics 2025 . The average Cartesian Therapeutics sales estimate is

$3.1m
Unlock
. This is
93.44% lower
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$20.0m 58.28%
Unlock
, the lowest is
$0.0 100.00%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 $38.9m 49.65%
2025
$3.1m 91.92%
Unlock
2026
$333k 89.40%
Unlock
2027
$0.0 100.00%
Unlock
2029
$112m 284.25%
Unlock

4 Cartesian Therapeutics Analysts have issued a net profit forecast 2025. The average Cartesian Therapeutics net profit estimate is

$-75.5m
Unlock
. This is
94.00% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-67.2m 94.66%
Unlock
, the lowest is
$-87.2m 93.07%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 $-107m 91.00%
2025
$-75.5m 29.47%
Unlock
2026
$-88.0m 16.57%
Unlock
2027
$-94.5m 7.37%
Unlock
2028
$-84.3m 10.87%
Unlock
2029
$-56.8m 32.63%
Unlock

Net Margin

2024 -275.18% 93.98%
2025
-2,403.04% 773.27%
Unlock
2026
-26,409.52% 999.00%
Unlock
2029
-50.59% 82.47%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Earnings Per Share $ -4.48 -3.16
91.00% 29.46%
P/E negative
EV/Sales 36.64

4 Analysts have issued a Cartesian Therapeutics forecast for earnings per share. The average Cartesian Therapeutics EPS is

$-3.16
Unlock
. This is
94.00% higher
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
$-2.81 94.66%
Unlock
, the lowest is
$-3.65 93.07%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 $-4.48 91.00%
2025
$-3.16 29.46%
Unlock
2026
$-3.68 16.46%
Unlock
2027
$-3.96 7.61%
Unlock
2028
$-3.53 10.86%
Unlock
2029
$-2.38 32.58%
Unlock

P/E ratio

Current -0.23 88.56%
2025
-3.91 1,600.00%
Unlock
2026
-3.35 14.32%
Unlock
2027
-3.12 6.87%
Unlock
2028
-3.50 12.18%
Unlock
2029
-5.20 48.57%
Unlock

Based on analysts' sales estimates for 2025, the Cartesian Therapeutics stock is valued at an EV/Sales of

36.64
Unlock
and an P/S ratio of
101.72
Unlock
.

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 2.40 128.57%
2025
36.64 1,426.48%
Unlock
2026
345.42 842.86%
Unlock
2029
1.03 73.98%
Unlock

P/S ratio

Current 6.67 118.73%
2025
101.72 1,425.37%
Unlock
2026
959.07 842.86%
Unlock
2029
2.85 73.97%
Unlock

Current Cartesian Therapeutics Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
HC Wainwright & Co.
Locked
Locked
Locked Mar 14 2025
Needham
Locked
Locked
Locked Mar 13 2025
HC Wainwright & Co.
Locked
Locked
Locked Jan 28 2025
Needham
Locked
Locked
Locked Jan 27 2025
Needham
Locked
Locked
Locked Jan 13 2025
BTIG
Locked
Locked
Locked Dec 19 2024
HC Wainwright & Co.
Locked
Locked
Locked Dec 04 2024
Analyst Rating Date
Locked
HC Wainwright & Co.:
Locked
Locked
Mar 14 2025
Locked
Needham:
Locked
Locked
Mar 13 2025
Locked
HC Wainwright & Co.:
Locked
Locked
Jan 28 2025
Locked
Needham:
Locked
Locked
Jan 27 2025
Locked
Needham:
Locked
Locked
Jan 13 2025
Locked
BTIG:
Locked
Locked
Dec 19 2024
Locked
HC Wainwright & Co.:
Locked
Locked
Dec 04 2024

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today